InterMune Licenses Hepatitis C Drug.(Infergen)(Brief Article)

InterMune Inc. agreed to license the FDA-approved hepatitis C therapeutic Infergen (interferon alfacon-1) from Amgen Inc. for $21 million in upfront payments, $8 million in nearterm milestones and royalties on sales. Amgen, of Thousand Oaks, Calif., granted InterMune, of Burlingame, Calif., exclusive rights to develop and commercialize Infergen and an …